Natural processing and presentation of the HOM-MEL-40/SSX2-derived p103-111 peptide. Natural processing and presentation of the HOM-MEL-40/SSX2-derived.

Slides:

Advertisements

Similar presentations

HOST DEFENCE AGAINST TUMORS:

Advertisements

T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a–specific, HLA-DRB3*0101–restricted CD4+ T cells by Maria Therese.

by Jennifer Couzin-Frankel

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells by Susanne M. Schmidt,

Volume 19, Issue 12, Pages (December 2011)

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators by Rikke Bæk Sørensen, Sine Reker Hadrup, Inge Marie Svane, Mads Christian.

A Promiscuous Survivin-Derived T-Cell Epitope Restricted to the HLA-A3 Super-Type Alleles Niels Junker, Shamaila Munir, Pia Kvistborg, Per thor Straten,

Targeting NY-ESO-1 epitopes restricted on multiple MHC alleles broadens the application of TCR gene therapy and makes it robust toward loss of heterozygosity.

Patient T cells recognise a SMAD4V370A-containing neoepitope presented by autologous cancer cells. Patient T cells recognise a SMAD4V370A-containing neoepitope.

CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib–associated renal carcinoma antigens with ubiquitous or restricted.

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Antigen Presenting Phenotype of Hodgkin Reed-Sternberg Cells: Analysis of the HLA Class I Processing Pathway and the Effects of Interleukin-10 on Epstein-Barr.

Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA by Caterina Milazzo, Volker L. Reichardt, Martin.

Volume 137, Issue 2, Pages (August 2009)

Mature dendritic cells pulsed with freeze–thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte.

Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients by Raffaella.

Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands

Triggering PD-1 in B cells suppresses tumor-specific immunity and promotes disease progression. Triggering PD-1 in B cells suppresses tumor-specific immunity.

Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia by Jochen Greiner, Yoko Ono, Susanne.

Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells by Martin R. Müller,

The absence of ADCC by nivolumab in vitro.

Volume 27, Issue 2, Pages (August 2007)

Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.

CpG Motifs Are Efficient Adjuvants for DNA Cancer Vaccines

Volume 13, Issue 2, Pages (February 2006)

Melanoma Inhibitor of Apoptosis Protein (ML-IAP) Specific Cytotoxic T Lymphocytes Cross-React with an Epitope from the Auto-Antigen SS56 Rikke Bæk Sørensen,

Mads Hald Andersen, Jürgen C. Becker, Per thor Straten

ADCC by T lymphocytes after transfection.

Comparison of ADCC by CD16V-transduced T lymphocytes and autologous NK cell. Comparison of ADCC by CD16V-transduced T lymphocytes and autologous NK cell.

IFN-γ–producing cells in the spleen and lungs postimmunization.

Restoration of the Expression of Transports Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity Juan Tao,

Molecular Therapy - Oncolytics

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

NOD.hCD205 mice are susceptible to T1D.

Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity. Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity.

Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors. Presence of anti-HPV E6/E7 epitope CD8+ T-cell responses in HPV+ OPSCC tumors.

BMS blocks functional responses in primary immune cells driven by IFNα

Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands

Antigen specificity of direct tumor recognition by HTLV-1 Tax–reactive HTLs. The peptide Tax reactive HTLs 5G, 8E, and 9B (A-C) and peptide Tax reactive.

Specific recognition of HOM-MEL-40/SSX2-derived p pulsed targets by p stimulated T-cells from patients with HOM-MEL-40/SSX2 positive breast.

by Jennifer Couzin-Frankel

Specificity of HOM-MEL-40/SSX2 p stimulated CD8+ T-cells.

Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.

CD91- and LOX-1-dependence of presentation of gp96-chaperoned peptides by MHC II. Presentation of gp96-chaperoned peptides by immature bone marrow-derived.

Cytotoxicity of p5399–107-induced CTL cells.

DCH-mediated cytotoxicity of isolated CD4+ and CD8+ T cells.

NY-ESO-1-specific cytotoxic reactivity of CD4+ T cell clones.

Direct recognition of MHC II/TARP14-27 on tumor cells by HTL

A2/Melan-A multimer+ CD8+ allorestricted CTL clones derived from donor DR fail to significantly recognize DR self-targets. A2/Melan-A multimer+ CD8+ allorestricted.

Increased levels of inflammation in mo-DCs translate into higher numbers of specific CD8 T-cell responses. Increased levels of inflammation in mo-DCs translate.

Specific inhibition of the Fab-HLA-A2/Flu induction of CTL mediated tumor cell lysis by a competing antibody. Specific inhibition of the Fab-HLA-A2/Flu.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Functional characterization of polyclonal Melan-A monospecific allorestricted CTLs. (A) Recognition of Melan-A peptides by the polyclonal Melan-A monospecific.

The differential susceptibility to CTL-induced lysis does not involve Melan-A antigen expression. The differential susceptibility to CTL-induced lysis.

HLA-A*0201 restriction of SSX2-derived p stimulated CD8+ T-cells.

Cytofluorometry analysis demonstrating the specific coating of anti-tumor Fab-HLA-A2/Flu conjugates on the surface of HLA-A2 negative tumor target cells,

Cytotoxic activity of CD8+ T-cells stimulated with SSX2-derived p

TET2 interacts with KLF1 transcription factor.

Effect of nivolumab or ipilimumab on immune responses to vaccination in cynomolgus monkeys. Effect of nivolumab or ipilimumab on immune responses to vaccination.

Frequency of misrepair studies with increasing concentrations of antibodies against NHEJ repair proteins. Frequency of misrepair studies with increasing.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Characterizing an A*1101-restricted SSC-specific CD8+ cytotoxic T-cell clone. Characterizing an A*1101-restricted SSC-specific CD8+ cytotoxic T-cell clone.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Vaccination schedule. Vaccination schedule. Vaccinations were given in cycles; each cycle consisted of four injections (vertical lines). Up to four additional.

Investigation of reactivity of D14 HLA-A

HLA restriction of spCD4 T-cell responses.

Location and modification of potential target peptides within PASD1.

Immunoblotting of human cancer cell lines pretyped by RT-PCR for CT10/MAGE-C2 mRNA expression with mAb LX-CT10.5 (NP-40 detergent lysates, chemiluminescence.

Design and operation of p.DOM-epitope vaccines.

Human monoclonal anti-NY-ESO-1 antibody (12D7) facilitates cross-presentation of a NY-ESO-1-derived, HLA-A2-restriced epitope (NY-ESO-1157–165). Human.

Presentation transcript:

Natural processing and presentation of the HOM-MEL-40/SSX2-derived p103-111 peptide. Natural processing and presentation of the HOM-MEL-40/SSX2-derived p103-111 peptide. (A) HLA-A*0201 restriction of SSX2-derived p103-111 stimulated CD8+ T-cells. COS7/A2 cells transfected with HOM-MEL-40/SSX2 were used as targets and EGFP-transfected cells served as a negative control in the ELISPOT assay. The reaction was blocked by adding the anti-pan human MHC-I antibody (clone W6/32) or the anti-HLA-A*02 antibody (clone BB7.2). (B) Recognition of the HLA-A*02 positive, SSX2 positive SK-MEL-37 cell line. The recognition of the cell line by SSX2-derived p103-111 stimulated T-cells was demonstrated by ELISPOT assay. The effect of a pretreatment of the SK-MEL-37 cells with IFN-gamma was tested. In order to block the reaction against SK-MEL-37, the anti-pan human MHC-I antibody (clone W6/32) was added. The tumor cell lines BT 549 (HLA-A*02+/SSX2-), T47D (HLA-A*02-/SSX2+) and ZR7530 (HLA-A*02-/SSX2-) were used as negative controls. Claudia Wagner et al. Cancer Immun 2003;3:18 Copyright © 2003 by Michael Pfreundschuh